A Patient Cohort With Locally Advanced or Metastatic Non-small Cell Lung Cancer Treated With Tarceva (Erlotinib) Monotherapy and Not Progressing After at Least 9 Months
Phase of Trial: Phase IV
Latest Information Update: 15 May 2015
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 18 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2013 Planned end date changed from 1 Jul 2016 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 06 Aug 2013 Planned end date changed from 1 Aug 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.